trending Market Intelligence /marketintelligence/en/news-insights/trending/xm1lZ3HEqUc58ZLsvOQBXw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Actinium closes offering of common stock, warrants

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Actinium closes offering of common stock, warrants

Actinium Pharmaceuticals Inc. closed its underwritten public offering of 21.5 million common shares and warrants to buy 18,275,000 common shares at 75 cents per share and related warrant.

The warrants have an exercise price of $1.05 per share and have a term of exercise of five years.

Gross proceeds from the offering were about $16.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by Actinium.

The company plans to use the net proceeds to fund clinical development of Iomab-B, Actimab-A, Actimab-M, its alpha particle technology platform and for general corporate purposes.

Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Maxim Group LLC and JonesTrading Institutional Services LLC acted as co-managers for the offering.